DNAnexus, Inc., provider of the Precision Health Data Cloud, and Galatea Bio, committed to 'Precision Health at Scale for All,' announced a strategic collaboration to enhance biomedical research and precision medicine.

Scale Biosciences (Scale Bio), announced the launch of the “100 Million Cell Challenge,” a global initiative aimed at pushing the boundaries of single-cell genomics research.

BioSpring GmbH and Pantherna Therapeutics GmbH, have agreed on a strategic collaboration in the field of research and development and signed a cooperation agreement mid-July.

Assay automation makes cutting-edge research more accessible to labs.

Strategic activation unites best-in-class technology with end-to-end development solutions to optimize therapeutic development process.

The teams aim to redefine plasmid sequencing with nanopore technology and global accessibility.

Touchlight, announced a license agreement with GSK. This agreement grants GSK non-exclusive rights to use Touchlight’s proprietary enzymatic dbDNA™ (doggybone DNA™) technology for the development and production of mRNA-based products.

Highly accurate long-read sequencing data will be used at Novogene’s new lab in Munich, supporting customers across a network of leading research institutions.

Zymo Research Corp., is excited to announce the launch of the Omics Discovery grant. This new initiative aims to empower scientists around the world with cuttingedge RNA sequencing (RNA-Seq) technologies to explore the transcriptome of ANY organism.

Eight-color kit provides more usable information from degraded or inhibited DNA samples. Includes all DNA markers recommended by the European Network of Forensic Science Institutes (ENFSI).